Abstract
An internal HTS effort identified a novel PDE2 inhibitor series that was subsequently optimized for improved PDE2 activity and off-target selectivity. The optimized lead, compound 4, improved cognitive performance in a rodent novel object recognition task as well as a non-human primate object retrieval task. In addition, co-crystallization studies of close analog of 4 in the PDE2 active site revealed unique binding interactions influencing the high PDE isoform selectivity.
Keywords:
Cognition; Optimization; PDE2; Phosphodiesterase inhibitor; Schizophrenia.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Acetic Acid / chemical synthesis
-
Acetic Acid / chemistry
-
Acetic Acid / pharmacology*
-
Animals
-
Catalytic Domain / drug effects
-
Cognitive Dysfunction / drug therapy*
-
Cognitive Dysfunction / metabolism
-
Cyclic Nucleotide Phosphodiesterases, Type 2 / antagonists & inhibitors*
-
Cyclic Nucleotide Phosphodiesterases, Type 2 / metabolism
-
Dose-Response Relationship, Drug
-
Indoles / chemical synthesis
-
Indoles / chemistry
-
Indoles / pharmacology*
-
Molecular Structure
-
Phosphodiesterase Inhibitors / chemical synthesis
-
Phosphodiesterase Inhibitors / chemistry
-
Phosphodiesterase Inhibitors / pharmacology*
-
Rats
-
Structure-Activity Relationship
Substances
-
Indoles
-
Phosphodiesterase Inhibitors
-
indole
-
Cyclic Nucleotide Phosphodiesterases, Type 2
-
Acetic Acid